Generalized pustular psoriasis (GPP) is the rarest form of psoriasis, a chronic autoimmune skin condition. Unlike other forms, GPP can be severe or even life-threatening. The disease causes flares of ...
This study presents a valuable advance by enabling functional mapping of Ca²⁺ responses in live human pancreatic tissue slices, providing new opportunities to study islet heterogeneity and ...
The FDA has approved the CD19+ B-cell targeted therapy inebilizumab-cdon (Uplizna, Amgen) for the treatment of adults with generalized myasthenia gravis (gMG) who test positive for anti-acetylcholine ...
Please provide your email address to receive an email when new articles are posted on . FDA approves inebilizumab-cdon for adults with anti-acetylcholine receptor and anti-muscle specific tyrosine ...
Scientists have achieved a “striking” reversal of Alzheimer’s disease in mice by restoring the normal function of the brain's vasculature—the network of blood vessels that supplies it with oxygen and ...
A rigorous new study finds that a single dose of LSD can ease anxiety and depression for months. The study involved 198 adults with generalized anxiety disorder, or GAD, a disabling form of anxiety ...
GPP patients have a nearly 5-fold increased mortality risk at 1 year and a 4-fold increased risk over long-term follow-up compared with the general population. The study underscores the need for ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
Nipocalimab (Imaavy; Johnson & Johnson), an FcRn-blocking monoclonal antibody, was approved for patients 12 years and older with generalized myasthenia gravis based on data from the ongoing ...
Stress, infections, and corticosteroid withdrawal are known triggers of generalized pustular psoriasis (GPP). However, doctors cannot attribute every GPP flare to a specific cause. Psoriasis is an ...
Autoimmune generalized myasthenia gravis is a disease that manifests with fluctuating muscle weakness. Inebilizumab is a monoclonal antibody that depletes CD19+ B cells, which are central to disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results